Isosorbide Mononitrate vs Dinitrate
For chronic angina management, isosorbide mononitrate (ISMN) is the preferred nitrate formulation due to superior pharmacokinetics, once-daily dosing that maintains efficacy without tolerance development, and better tolerability compared to isosorbide dinitrate (ISDN).
Key Differences in Pharmacology and Clinical Use
Isosorbide Mononitrate (ISMN)
- Active metabolite of ISDN with 100% bioavailability
- Once-daily dosing with controlled-release formulations (60-240 mg) provides 12+ hours of antianginal coverage 11
- No tolerance development when given once daily in the morning 12
- Peak effect at 3-4 hours post-dose with sustained activity 1
- Better tolerated with fewer headaches during chronic therapy 3
Isosorbide Dinitrate (ISDN)
- Requires hepatic metabolism to active mononitrate metabolites
- Multiple daily doses needed (typically 20-30 mg three times daily) 4
- Significant tolerance develops with regular dosing—efficacy limited to ~2 hours after each dose during chronic use 4
- Asymmetric dosing (7 AM, 1 PM, 6 PM) provides only ~6 hours of daily antianginal protection 2
- Higher incidence of headaches requiring discontinuation 5
Clinical Indications
Chronic Angina (Chronic Coronary Syndrome)
Both formulations are recommended as second-line antianginal therapy after beta-blockers and/or calcium channel blockers 6. However:
- ISMN 60-120 mg once daily is preferred for prophylaxis due to sustained 12-hour efficacy without tolerance 15
- ISDN requires asymmetric dosing (leaving 14+ hour nitrate-free interval) to minimize tolerance 4
- Short-acting nitrates remain first-line for acute symptom relief 6
Heart Failure
- ISDN + hydralazine combination (not ISMN) is the evidence-based regimen for HFrEF, particularly in self-identified Black patients 7
- Target dose: 40 mg ISDN three times daily (120 mg total) + 75 mg hydralazine three times daily 7
- ISMN monotherapy is NOT recommended for heart failure with preserved ejection fraction—it actually decreased activity levels and provided no benefit 8
Practical Dosing Algorithms
For Chronic Angina Prophylaxis:
- Start ISMN controlled-release 30-60 mg once daily in the morning
- Titrate to 120 mg once daily if needed for symptom control 1
- Maximum studied dose: 240 mg once daily 1
- Maintain once-daily morning dosing to preserve efficacy and avoid tolerance
If Using ISDN (less preferred):
- Use asymmetric dosing only: 20-30 mg at 7 AM, 1 PM, and 6 PM
- This provides ~6 hours of coverage but leaves overnight gap 42
- Expect partial tolerance even with asymmetric dosing 2
Critical Caveats
Absolute contraindications for both formulations:
- Concomitant phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil)—risk of severe hypotension 6
- Hypertrophic cardiomyopathy 6
Tolerance considerations:
- ISDN develops marked tolerance with symmetric (every 6-8 hours) or QID dosing 42
- ISMN maintains efficacy with once-daily dosing but loses effectiveness with BID or TID regimens 2
- The nitrate-free interval is essential—ISMN's once-daily regimen naturally provides this overnight
Comparative efficacy:
- Head-to-head trials show ISMN 60 mg once daily equals or exceeds ISDN 20 mg TID for exercise tolerance 5
- ISMN requires 1.5-2 times lower total daily dose than ISDN for equivalent effect 9
- ISMN provides more consistent antianginal coverage throughout the dosing interval 3
Bottom Line for Clinical Practice
Choose ISMN controlled-release 60-120 mg once daily for chronic angina prophylaxis—it offers superior convenience, sustained efficacy without tolerance, and better tolerability. Reserve ISDN specifically for the combination therapy with hydralazine in heart failure with reduced ejection fraction, where it has proven mortality benefit 7. Both formulations are contraindicated with PDE-5 inhibitors and in hypertrophic cardiomyopathy 6.